New features in MEK retinopathy

Ocular toxicities of MEK inhibitors and other targeted therapies

(2016) N. Stjepanovic et al.   ANNALS OF ONCOLOGY

MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects

(2016) U. Urner-Bloch et al.   EUROPEAN JOURNAL OF CANCER

Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer

(2016) Marissa L. Weber et al.   JAMA Ophthalmology

Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series

(2015) Alfredo Niro et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity

(2015) K E Duncan et al.   EYE

Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma

(2015) Elon H.C. van Dijk et al.   OPHTHALMOLOGY

Transient MEK inhibitor-associated retinopathy in metastatic melanoma

(2014) U. Urner-Bloch et al.   ANNALS OF ONCOLOGY

Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma

(2014) A. M. Menzies et al.   CLINICAL CANCER RESEARCH

Cell Models to Study Regulation of Cell Transformation in Pathologies of Retinal Pigment Epithelium

(2014) Alla V. Kuznetsova et al.   Journal of Ophthalmology

Effect of inhibition of the FGFR–MAPK signaling pathway on the development of ocular toxicities

(2013) Ruud van der Noll et al.   CANCER TREATMENT REVIEWS

Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma

(2011) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

MEK/ERK pathway mediates UVB-induced AQP1 downregulation and water permeability impairment in human retinal pigment epithelial cells

(2009) Jiang   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

PD0325901, a Mitogen-Activated Protein Kinase Kinase Inhibitor, Produces Ocular Toxicity in a Rabbit Animal Model of Retinal Vein Occlusion

(2009) Wenhu Huang et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS